Investor Overview

Hemostemix is on track to becoming the first company to commercialize an autologous cell therapy for critical limb ischemia.

Download Corporate Presentation July-2018

Stock Info

HEM
TSX-V
0.060
-0.010
Data as of
Minimum 20 minute delay